Despite considerable advances in early diagnosis, prostate cancer (PCa) remains the second leading cause of cancer-related deaths in men in western countries. In fact, although efficient therapies exist for early-stage disease, the treatment of advanced PCa remains unsuccessful mainly due to its poor responsiveness to anti-cancer agents. This evidence underlines the urgent need for the development of novel and more effective therapeutic approaches. In this context, the documented dysregulation of microRNAs (miRNAs) -which are short non-coding RNAs that regulate gene expression at post-transcriptional level-in PCa, together with their potential to simultaneously regulate multiple oncogenic/tumor-suppressive pathways, has stimulated interest in defining a functional association between altered expression of specific miRNAs and the response of PCa to anti-cancer agents. The purpose of this review is to provide an overview on PCa-related miRNAs as potential novel therapeutic targets/tools, with a special focus on the role that they may play in conditioning the responsiveness of PCa to anti-cancer drugs.
MicroRNAs and the Response of Prostate Cancer to Anti-Cancer Drugs / M. Pennati, M. Folini, P. Gandellini, N. Zaffaroni. - In: CURRENT DRUG TARGETS. - ISSN 1389-4501. - 17:3(2016), pp. 257-265. [10.2174/1389450116666150316223341]
MicroRNAs and the Response of Prostate Cancer to Anti-Cancer Drugs
P. Gandellini;
2016
Abstract
Despite considerable advances in early diagnosis, prostate cancer (PCa) remains the second leading cause of cancer-related deaths in men in western countries. In fact, although efficient therapies exist for early-stage disease, the treatment of advanced PCa remains unsuccessful mainly due to its poor responsiveness to anti-cancer agents. This evidence underlines the urgent need for the development of novel and more effective therapeutic approaches. In this context, the documented dysregulation of microRNAs (miRNAs) -which are short non-coding RNAs that regulate gene expression at post-transcriptional level-in PCa, together with their potential to simultaneously regulate multiple oncogenic/tumor-suppressive pathways, has stimulated interest in defining a functional association between altered expression of specific miRNAs and the response of PCa to anti-cancer agents. The purpose of this review is to provide an overview on PCa-related miRNAs as potential novel therapeutic targets/tools, with a special focus on the role that they may play in conditioning the responsiveness of PCa to anti-cancer drugs.File | Dimensione | Formato | |
---|---|---|---|
Pennati _Curr Drug Targets.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
299.74 kB
Formato
Adobe PDF
|
299.74 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.